SEC Company Response from aTYR PHARMA INC (ATYR) (CIK 0001339970) (ATYR) — Jun 20, 2016
aTYR PHARMA INC (ATYR) (CIK 0001339970)
Date: June 20, 2016 · CIK: 0001339970 · Accession: 0001193125-16-626827
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-211998
Letter
VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Attention: Suzanne Hayes, Assistant Director Christina Thomas Re: aTyr Pharma, Inc. Acceleration Request for Registration Statement on Form S-3 File No. 333-211998
Dear Ms. Hayes:
Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), aTyr Pharma, Inc. (the “Company”) hereby requests that the effective date and time of the above-referenced registration statement (the “Registration Statement”) be accelerated to June 22, 2016, at 4:00 p.m., Eastern Time, or at such later time as the Company or its counsel, Goodwin Procter LLP, may orally request via telephone call to the staff of the Division of Corporation Finance of the Securities and Exchange Commission (the “Commission”). Once the Registration Statement is effective, please orally confirm the event with our counsel, Goodwin Procter LLP, by calling Mitzi Chang at (415) 733-6017. We also respectfully request that a copy of the written order from the Commission verifying the effective time and date of the Registration Statement be sent to our counsel, Goodwin Procter LLP, Attention: Mitzi Chang, by facsimile to (415) 384-6006.
In connection with the foregoing, the Company hereby acknowledges the following:
•
should the Commission or the staff of the Commission, acting pursuant to delegated authority, declare the Registration Statement effective, it does not foreclose the Commission from taking any action with respect to the Registration Statement;
•
the action of the Commission or the staff of the Commission, acting pursuant to delegated authority, in declaring the Registration Statement effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the Registration Statement; and
•
the Company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
If you have any questions regarding this request, please contact Mitzi Chang of Goodwin Procter LLP at (415) 733-6017.
Sincerely,
ATYR PHARMA, INC.
Show Raw Text
CORRESP
1
filename1.htm
CORRESP
aTyr Pharma, Inc.
3545 John Hopkins Court, Suite #250
San Diego, CA 92121
VIA EDGAR
June 20, 2016
United States Securities and Exchange
Commission
Division of Corporation Finance
100 F Street,
N.E.
Washington, DC 20549
Attention: Suzanne Hayes,
Assistant Director
Christina Thomas
Re:
aTyr Pharma, Inc.
Acceleration Request for Registration Statement on Form
S-3
File No. 333-211998
Dear Ms. Hayes:
Pursuant to Rule 461
under the Securities Act of 1933, as amended (the “Act”), aTyr Pharma, Inc. (the “Company”) hereby requests that the effective date and time of the above-referenced registration statement (the “Registration
Statement”) be accelerated to June 22, 2016, at 4:00 p.m., Eastern Time, or at such later time as the Company or its counsel, Goodwin Procter LLP, may orally request via telephone call to the staff of the Division of Corporation
Finance of the Securities and Exchange Commission (the “Commission”). Once the Registration Statement is effective, please orally confirm the event with our counsel, Goodwin Procter LLP, by calling Mitzi Chang at
(415) 733-6017. We also respectfully request that a copy of the written order from the Commission verifying the effective time and date of the Registration Statement be sent to our counsel, Goodwin Procter LLP, Attention: Mitzi Chang, by
facsimile to (415) 384-6006.
In connection with the foregoing, the Company hereby acknowledges the following:
•
should the Commission or the staff of the Commission, acting pursuant to delegated authority, declare the Registration Statement effective, it does not foreclose the Commission from taking any action with respect to the
Registration Statement;
•
the action of the Commission or the staff of the Commission, acting pursuant to delegated authority, in declaring the Registration Statement effective, does not relieve the Company from its full responsibility for the
adequacy and accuracy of the disclosure in the Registration Statement; and
•
the Company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
If you have any questions regarding this request, please contact Mitzi Chang of Goodwin Procter LLP at (415) 733-6017.
Sincerely,
ATYR PHARMA, INC.
/s/ John T. Blake
John T. Blake
Vice President, Finance
cc:
John D. Mendlein, Ph.D. (aTyr Pharma, Inc.)
Nancy Krueger (aTyr Pharma, Inc.)
Mitzi Chang (Goodwin Procter LLP)